OPKO Health, Inc.(OPK), a multinational biopharmaceutical and diagnostics company, Wednesday said it agreed to buy PROLOR Biotech, Inc.(PBTH), a clinical stage biopharmaceutical company for about $480 million or $7 per share of PROLOR, in an all-stock deal. Through this, OPKO could gain PROLOR's long-acting version of human growth hormone, hGH-CTP, which is in late-stage trials.
Following the agreement, PROLOR shareholders will receive 0.9951 shares of OPKO for each share of PROLOR common stock. This is priced at $7.03 per share of OPKO common stock.
Phillip Frost, CEO of OPKO said,"With the inclusion of PROLOR's pipeline, OPKO will have four significant products in Phase III clinical development and a robust pipeline of important therapeutic and unique diagnostic products in various stages of development. PROLOR's drug-product candidates for growth hormone deficiency, hemophilia, obesity and diabetes, along with its broadly applicable technology platforms and efficient research and development center are highly valuable assets that will complement OPKO's strategy."
Barrington Research Associates, Inc., acted as the financial advisor to OPKO Health. Jefferies LLC acted as financial advisor to PROLOR Biotech and the Strategic Alternatives Committee on the transaction.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.